Screening of Potential Probiotic Lactobacillaceae and Their Improvement of Type 2 Diabetes Mellitus by Promoting PI3K/AKT Signaling Pathway in db/db Mice.

Polish journal of microbiology Pub Date : 2023-09-20 eCollection Date: 2023-09-01 DOI:10.33073/pjm-2023-028
Yueyang Li, Tong Tong, Peifan Li, Yian Peng, Michael Zhang, Jia Liu, Yongxin She, Zuming Li, Yongli Li
{"title":"Screening of Potential Probiotic <i>Lactobacillaceae</i> and Their Improvement of Type 2 Diabetes Mellitus by Promoting PI3K/AKT Signaling Pathway in db/db Mice.","authors":"Yueyang Li,&nbsp;Tong Tong,&nbsp;Peifan Li,&nbsp;Yian Peng,&nbsp;Michael Zhang,&nbsp;Jia Liu,&nbsp;Yongxin She,&nbsp;Zuming Li,&nbsp;Yongli Li","doi":"10.33073/pjm-2023-028","DOIUrl":null,"url":null,"abstract":"<p><p>The study aimed to isolate <i>Lactobacillaceae</i> strains with <i>in vitro</i> hypoglycemic activity and probiotic properties and to determine their antidiabetic abilities <i>in vivo</i>. <i>Lactiplantibacillus plantarum</i> 22, <i>L. plantarum</i> 25, <i>Limosilactobacillus fermentum</i> 11, and <i>L. fermentum</i> 305 with high <i>in vitro</i> hypoglycemic activity were screened from 23 strains of <i>Lactobacillaceae</i> isolated from human feces and identified by 16S rDNA sequencing. The fasting blood glucose (FBG) of the mice was recorded weekly. After 12 weeks, liver, kidney, and pancreas tissues were stained with hematoxylin and eosin (H&E) to observe histomorphology; the inflammatory factors were assayed by Quantitative Real-time PCR; PI3K and AKT were measured by Western blot; the short-chain fatty acids (SCFAs) were determined by LC-MS/MS. Inhibitory activities of <i>L. plantarum</i> 22, <i>L. plantarum</i> 25, <i>L. fermentum</i> 11, and <i>L. fermentum</i> 305 against α-amylase were 62.29 ± 0.44%, 51.81 ± 3.65%, 58.40 ± 1.68%, and 57.48 ± 5.04%, respectively. Their inhibitory activities to α-glucosidase were 14.89 ± 0.38%, 15.32 ± 0.89%, 52.63 ± 3.07%, and 51.79 ± 1.13%, respectively. Their survival rate after simulated gastrointestinal test were 12.42 ± 2.84%, 9.10 ± 1.12%, 5.86 ± 0.52%, and 8.82 ± 2.50% and their adhesion rates to Caco-2 cell were 6.09 ± 0.39%, 6.37 ± 0.28%, 6.94 ± 0.27%, and 6.91 ± 0.11%, respectively. The orthogonal tests of bacterial powders of the four strains showed that the maximum inhibitory activities to α-amylase and α-glucosidase were 93.18 ± 1.19% and 75.33 ± 2.89%, respectively. The results showed that the mixture of <i>Lactobacillaceae</i> could lower FBG, reduce inflammation, and liver, kidney, and pancreas damage, promote PI3K/AKT signaling pathway, and increase the content of SCFAs. The combination of <i>L. plantarum</i> 22, <i>L. plantarum</i> 25, <i>L. fermentum</i> 11, and <i>L. fermentum</i> 305 can potentially improve type 2 diabetes mellitus (T2DM).</p>","PeriodicalId":94173,"journal":{"name":"Polish journal of microbiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/4f/pjm-72-3-pjm-2023-028.PMC10508973.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polish journal of microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33073/pjm-2023-028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The study aimed to isolate Lactobacillaceae strains with in vitro hypoglycemic activity and probiotic properties and to determine their antidiabetic abilities in vivo. Lactiplantibacillus plantarum 22, L. plantarum 25, Limosilactobacillus fermentum 11, and L. fermentum 305 with high in vitro hypoglycemic activity were screened from 23 strains of Lactobacillaceae isolated from human feces and identified by 16S rDNA sequencing. The fasting blood glucose (FBG) of the mice was recorded weekly. After 12 weeks, liver, kidney, and pancreas tissues were stained with hematoxylin and eosin (H&E) to observe histomorphology; the inflammatory factors were assayed by Quantitative Real-time PCR; PI3K and AKT were measured by Western blot; the short-chain fatty acids (SCFAs) were determined by LC-MS/MS. Inhibitory activities of L. plantarum 22, L. plantarum 25, L. fermentum 11, and L. fermentum 305 against α-amylase were 62.29 ± 0.44%, 51.81 ± 3.65%, 58.40 ± 1.68%, and 57.48 ± 5.04%, respectively. Their inhibitory activities to α-glucosidase were 14.89 ± 0.38%, 15.32 ± 0.89%, 52.63 ± 3.07%, and 51.79 ± 1.13%, respectively. Their survival rate after simulated gastrointestinal test were 12.42 ± 2.84%, 9.10 ± 1.12%, 5.86 ± 0.52%, and 8.82 ± 2.50% and their adhesion rates to Caco-2 cell were 6.09 ± 0.39%, 6.37 ± 0.28%, 6.94 ± 0.27%, and 6.91 ± 0.11%, respectively. The orthogonal tests of bacterial powders of the four strains showed that the maximum inhibitory activities to α-amylase and α-glucosidase were 93.18 ± 1.19% and 75.33 ± 2.89%, respectively. The results showed that the mixture of Lactobacillaceae could lower FBG, reduce inflammation, and liver, kidney, and pancreas damage, promote PI3K/AKT signaling pathway, and increase the content of SCFAs. The combination of L. plantarum 22, L. plantarum 25, L. fermentum 11, and L. fermentum 305 can potentially improve type 2 diabetes mellitus (T2DM).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
潜在益生菌乳酸杆菌的筛选及其通过促进db/db小鼠PI3K/AKT信号通路改善2型糖尿病的作用。
本研究旨在分离具有体外降血糖活性和益生菌特性的乳酸杆菌科菌株,并测定其体内抗糖尿病能力。从23株人粪便乳酸杆菌中筛选出具有较高体外降血糖活性的植物乳杆菌22、植物乳杆菌25、发酵乳杆菌11和发酵乳杆菌305,并通过16S rDNA测序进行鉴定。每周记录小鼠的空腹血糖(FBG)。12周后,用苏木精和伊红(H&E)对肝、肾和胰腺组织进行染色,观察组织形态学;实时定量PCR法检测炎症因子;免疫印迹法测定PI3K和AKT;采用LC-MS/MS法测定短链脂肪酸(SCFAs)。植物乳杆菌22、植物乳杆菌25、发酵乳杆菌11和发酵乳杆菌305对α-淀粉酶的抑制活性分别为62.29±0.44%、51.81±3.65%、58.40±1.68%和57.48±5.04%。它们对α-葡萄糖苷酶的抑制活性分别为14.89±0.38%、15.32±0.89%、52.63±3.07%和51.79±1.13%。模拟胃肠道试验后的存活率分别为12.42±2.84%、9.10±1.12%、5.86±0.52%和8.82±2.50%,对Caco-2细胞的粘附率分别为6.09±0.39%、6.37±0.28%、6.94±0.27%和6.91±0.11%。正交试验表明,四株菌株对α-淀粉酶和α-葡萄糖苷酶的最大抑制活性分别为93.18±1.19%和75.33±2.89%。结果表明,乳酸杆菌混合制剂可降低FBG,减轻炎症,减轻肝、肾、胰腺损伤,促进PI3K/AKT信号通路,增加SCFAs含量。植物乳杆菌22、植物乳杆菌25、发酵乳杆菌11和发酵乳杆菌305的组合可以潜在地改善2型糖尿病(T2DM)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Comprehensive Analysis of Codon Usage Bias in Human Papillomavirus Type 51. Distribution and Molecular Characterization of Antibiotic-Resistant Pseudomonas aeruginosa in Hospital Settings of Sulaymaniyah, Iraq. Activity of Fluoroquinolones and Proton Pump Inhibitors against Resistant Oral Bacterial Biofilms, in silico and in vitro Analysis. Identification of a Novel Parvovirus in the Arctic Wolf (Canis lupus arctos). Methodological Evaluation of Carbapenemase Detection by Different Methods.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1